Please see the information listed below regarding the Covid-19 vaccine.
Patients in priority groups 1 – 9 should have received an invite – if not contact the surgery.
Priority group 1 – Residents in a care home for older adults Staff working in care homes for older adults
Priority group 2 – All those 80 years of age and over Frontline health and social care workers*
Priority group 3 – All those 75 years of age and over
Priority group 4 – All those 70 years of age and over Clinically extremely vulnerable individuals (not including those under 16 years of age)**
Priority group 5 – All those 65 years of age and over
Priority group 6 – Adults aged 16 to 65 years in an at risk group (below)
Priority group 7- All those 60 years of age and over
Priority group 8 – All those 55 years of age and over
Priority group 9 – All those 50 years of age and over
- *evidence of employment may be requested **see link for details: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19#cev
- Housebound patients are being dealt with by the community home-visiting team.
- People in priority group 6 are currently being called
- No need to contact us and will be called in due course as vaccine supplies are made available: These are Adults aged 16 to 65 years in an at-risk group (risk groups below)
- Chronic respiratory disease – Individuals with a severe lung condition, including those with asthma that requires continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission, and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and Broncho pulmonary dysplasia (BPD).
- Chronic heart disease and vascular disease – Congenital heart disease, hypertension with cardiac complications, chronic heart failure, individuals requiring regular medication and/or follow-up for ischaemic heart disease. This includes individuals with atrial fibrillation, peripheral vascular disease or a history of venous thromboembolism.
- Chronic kidney disease – Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, kidney transplantation.
- Chronic liver disease – Cirrhosis, biliary atresia, chronic hepatitis.
- Chronic neurological disease – Stroke, transient ischaemic attack (TIA). Conditions in which respiratory function may be compromised due to neurological disease (e.g. polio syndrome sufferers). This includes individuals with cerebral palsy, severe or profound learning disabilities, Down’s Syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability.
- Diabetes mellitus – Any diabetes, including diet-controlled diabetes.
- Immunosuppression – Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID). Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil. Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults. Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma and those with systemic lupus erythematosus and rheumatoid arthritis, and psoriasis who may require long term immunosuppressive treatments. Most of the more severely immunosuppressed individuals in this group should already be flagged as CEV. Individuals who are not yet on the CEV list but who are about to receive highly immunosuppressive interventions or those whose level of immunosuppression is about to increase may be therefore be offered vaccine alongside the CEV group, if therapy can be safely delayed or there is sufficient time (ideally two weeks) before therapy commences. Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV).
- Asplenia or dysfunction of the spleen – This also includes conditions that may lead to splenic dysfunction, such as homozygous sickle cell disease, thalassemia major and coeliac syndrome.
- Morbid obesity – Adults with a Body Mass Index ≥40 kg/m².
- Severe mental illness – Individuals with schizophrenia or bipolar disorder, or any mental illness that causes severe functional impairment.
- Adult carers – Those who are eligible for a carer’s allowance, or those who are the sole or primary carer of an elderly or disabled person who is at increased risk of COVID-19 mortality and therefore clinically vulnerable.
- Younger adults in long-stay nursing and residential care settings – Many younger adults in residential care settings will be eligible for vaccination because they fall into one of the clinical risk groups above (for example learning disabilities). Given the likely high risk of exposure in these settings, where a high proportion of the population would be considered eligible, vaccination of the whole resident population is recommended. Younger residents in care homes for the elderly will be at high risk of exposure, and although they may be at lower risk of mortality than older residents should not be excluded from vaccination programmes (see priority 1 above).